Systemic therapy in the management of metastatic or advanced salivary gland cancers

Head and Neck Oncology

Volumn 4, Issue 1, 2012, Pages

  Lagha, Aymen ^a   Chraiet, Nesrine ^a   Ayadi, Mouna ^a   Krimi, Sarra ^a   Allani, Bassem ^a   Rifi, Hela ^a   Raies, Henda ^a   Mezlini, Amel ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

Adenocarcinoma; Adenocystic; Chemotherapy; Hormonotherapy; Mucoepidermoid; Review; Salivary glands; Targeted therapy; Treatment

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIANDROGEN; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LAPATINIB; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PIRARUBICIN; PROTEASOME; PROTEIN TYROSINE KINASE; TAMOXIFEN; TRASTUZUMAB; VINCRISTINE;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADVANCED CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DIARRHEA; DRUG MECHANISM; HORMONAL THERAPY; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; METASTASIS; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SALIVARY GLAND CANCER; SKIN TOXICITY; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; SALIVARY GLAND NEOPLASMS;

EID: 84860536531     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-4-19     Document Type: Review

References (97)

1. Systemic therapy in the palliative management of advanced salivary gland cancers. Laurie SA, Licitra L, J Clin Oncol 2006 24 2673 2678 10.1200/JCO.2005.05.3025 16763282 (Pubitemid 46622089)
2. Major and minor salivary gland tumors. Guzzo M, Locati LD, Prott FJ, et al. Critical reviews in Oncology/Hematology 2010 74 134 148 10.1016/j. critrevonc.2009.10.004 19939701
3. 3-Tumours of the Salivary Glands. Pathology and Genetics of Head and Neck Tumours World Health Organization, Lyon, Barnes L, Eveson JW, Reichart P, Sidransky D, 2005 209
4. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Sung MW, Kim KH, Kim JW, et al. Arch Otolaryngol Head Neck Surg 2003 129 1193 1197 10.1001/archotol.129.11.1193 14623749 (Pubitemid 37433155)
5. HO AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Laurie SA, Lancet Oncol 2011 12 815 824 10.1016/S1470- 2045(10)70245-X 21147032
6. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Terhaard CH, Lubsen H, Van der Tweel I, et al. Head Neck 2004 26 681 692 10.1002/hed.10400 15287035 (Pubitemid 39014632)
7. Cisplatin in advanced salivary gland carcinoma: a phase II study of 25 patients. Licitra L, Marchini S, Spinazze S, et al. Cancer 1991 68 1874 1877 10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S 1913539
8. Cisplatin therapy for adenoid cystic carcinoma. Schramm VL, Scrodes C, Myers EN, Arch Otolaryngol 1981 107 739 741 10.1001/archotol.1981.00790480015004 6274284 (Pubitemid 12245992)
9. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. De Haan LD, De Mulder PH, Vermorken JB, et al. Head neck 1992 14 273 277 10.1002/hed.2880140403 1381339
10. Southwest oncology group study of Mitoxantrone for the treatment of patients with advanced adenoid cystic carcinoma of the head and neck. Mattox DE, Von Hoff D, Balcerzak SP, Invest new drugs 1990 8 105 107 2160919 (Pubitemid 20087254)
11. de Mulder PM, de Graeff A et al. Verweii J, Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and neck Cancer Cooperative Group. Ann Oncol 1996 7 867 869
12. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC head and neck Cancer Cooperative Group. Vermorken JB, Verweij J, de Mulder PH, et al. Ann Oncol 1993 4 785 788 8280659 (Pubitemid 23340091)
13. Chemotherapy for salivary gland cancer. Suen JY, Johns ME, Laryngoscope 1982 92 235 239 6279995 (Pubitemid 12187092)
14. Chemotherapy for salivary gland cancer. Kaplan MJ, Johns ME, Cantrell RW, Otolaryngol Head Neck Surg 1986 95 165 170 3035459 (Pubitemid 16025390)
15. Phase II randomised trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Airoldi M, Pedani F, Succo G, et al. Cancer 2001 91 541 547 10.1002/1097-0142(20010201)91: 3<541::AID-CNCR1032>3.0.CO;2-Y 11169936 (Pubitemid 32105699)
16. Metastatic adenoid cystic carcinoma of salivary glands: case reports and review of literature. Spiers ASD, Esseltine DLW, Ruckdeschel JC, Davies JNP, Horton J, Cancer Control 1996 3 4 336 342 10765225 (Pubitemid 26302012)
17. Chemotherapy for adenocystic carcinoma. Tannock IF, Sutherland DJ, Cancer 1980 46 452 454 10.1002/1097-0142(19800801)46:3<452::AID- CNCR2820460305>3.0.CO;2-Z 6249480 (Pubitemid 10036634)
18. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Gilbert J, Li Y, Pinto HA, et al. Head Neck 2006 28 197 204 10.1002/hed.20327 16470745 (Pubitemid 43269885)
19. Docetaxel (taxotere) in recurrent high grade mucoepidermoid carcinoma of the major salivary glands. Raguse J, Gath HJ, Bier J, Riess H, Oettle H, Oral Oncology Extra. 2004 40 5 7 10.1016/S1741-9409(03)00003-7 (Pubitemid 41151944)
20. Docetaxel in the treatment of metastatic carcinoma of the salivary glands report of a case. Belli F, Di Lauro L, Zappanico A, Giunta S, Clin Ter. 1999 150 1 77 79 10367547 (Pubitemid 29230454)
21. Buter j, et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Van Herpen CM, Locati LD, Eur J Cancer 2008 44 2542 2545 10.1016/j.ejca.2008.08.014 18819792
22. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Alberts DS, Manning MR, Coulthared SW, et al. Cancer 1981 47 645 648 10.1002/1097-0142(19810215)47:4<645::AID- CNCR2820470404>3.0.CO;2-A 7194729
23. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Dreyfuss AI, Clark JR, Fallon BG, et al. Cancer 1987 60 2869 2872 10.1002/1097-0142(19871215)60:12<2869::AID- CNCR2820601203>3.0.CO;2-Y 2824016 (Pubitemid 18005856)
24. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Belani CP, Eisenberger MA, Gray WC, Med Pediatr Oncol 1988 16 197 202 10.1002/mpo.2950160309 2837623
25. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Creagan ET, Woods JE, Rubin J, et al. Cancer 1988 62 2313 2319 10.1002/1097-0142(19881201)62:11<2313::AID- CNCR2820621110>3.0.CO;2-4 3179947
26. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma: aphase II trial of 22 patients. Licitra L, Cavina R, Grandi C, et al. Ann Oncol 1996 7 640 642 10.1093/oxfordjournals.annonc.a010684 8879381 (Pubitemid 26285647)
27. Supporting evidence for an active treatment program for advanced salivary gland carcinoma. Eisenberger MA, Cancer Treat Rep 1985 69 319 321 3884153 (Pubitemid 15080819)
28. Cisplatin, doxorubicin and 5-fluoruracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. Venook AP, Tseng A, Meyers FJ, et al. J Clin Oncol 1987 5 951 955 3585449 (Pubitemid 17120002)
29. Fluorouracil, doxorubicin, cyclophosphamide and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. Dimery IW, Legha SS, Shirinian L, et al. J clin Oncol 1990 8 1056 1062 2112183 (Pubitemid 20200194)
30. Cisplatin, epirubicin anf 5-fluouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Airoldi M, Pedani F, Brando V, et al. Tumori 1989 75 252 256 2475951 (Pubitemid 19192950)
31. Epirubicin, cisplatin and protacted venous infusion 5-fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Ross PJ, Teoh EM, AHern RP, et al. Clin Oncol (R Coll Radiol) 2009 21 311 314 10.1016/j.clon.2008. 12.009
32. Chemotherapy for recurrent adeno and adenoidcystic carcinomas in the head and neck. Tsukuda M, Kokatsu T, Ito K, et al. J cancer Res Clin Oncol 1993 119 756 758 10.1007/BF01195348 8408188 (Pubitemid 23290466)
33. Chemotherapy for advanced salivary gland neoplasms. Posner MR, Ervin TJ, Weichselbaum RR, et al. Cancer 1982 50 2261 2264 10.1002/1097-0142(19821201)50: 11<2261::AID-CNCR2820501105>3.0.CO;2-E 6754060 (Pubitemid 13244155)
34. Fluoruracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Triozzi PL, Brantley A, Fisher S, et al. Cancer 1987 59 887 890 10.1002/1097-0142(19870301)59:5<887::AID-CNCR2820590505>3. 0.CO;2-8 2434202 (Pubitemid 17024639)
35. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Hill ME, Constenla DO, AHern RP, et al. Oral Oncol 1997 33 275 278 10.1016/S0964-1955(97)00026-2 9307718 (Pubitemid 27376851)
36. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Airoldi M, Fornari G, Fedani F, et al. Anticancer Res. 2000 20 3781 3783 11268454 (Pubitemid 32002275)
37. Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Ruzich JC, Ciesla MC, Clark JL, Head Neck 2002 24 406 410 10.1002/hed.10034 11933184 (Pubitemid 34260047)
38. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Gedlicka C, Schull B, Formanek M, et al. Anticancer Drugs 2002 13 491 495 10.1097/00001813-200206000-00007 12045460 (Pubitemid 34621053)
39. A phase II study of platinium and gemcitabine in advanced salivary gland cancers: a trial of the NCIC Clinical trials Group. Laurie SA, Siu LL, Winquist E, et al. Cancer 2010 116 362 368 10.1002/cncr.24745 19924794
40. A randomized phase II trial of Epirubicin and 5-Fluorouracil versus Cisplatinum in the palliation of advanced and recurrent malignant tumor of the salivary glands. Jones AS, Phillips DE, Cook JA, Helliwell TR, Br J Cancer 1993 67 112 114 10.1038/bjc.1993.19 7678976 (Pubitemid 23034933)
41. Cisplatin+irinotecan in recurrent/metastatic salivary gland malignancies. Pedani F, Airoldi M, Marchionatti S, Bumma C, European Journal of Cancer Supplements 2003 1 5 44-
42. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mino M, Pilch BZ, Faquin WC, Mod Pathol 2003 16 12 1224 1231 10.1097/01.MP.0000096046.42833.C7 14681323 (Pubitemid 38018604)
43. Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies. Dodd RL, Slevin NJ, Oral Oncology 2006 42 759 769 10.1016/j.oraloncology.2006.01.001 16757203 (Pubitemid 44307768)
44. Kit protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Holst VA, Marshall CE, Moskaluk CA, et al. Mod Pathol 1999 12 956 960 10530560 (Pubitemid 29485269)
45. Expression of the c-kit protein is associated with certain sub-types of salivary gland carcinoma. Jeng YM, Lin CY, Hsu HC, Cancer Lett 2000 154 107 111 10.1016/S0304-3835(00)00387-6 10799746 (Pubitemid 30229916)
46. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Edwards PC, Bhuiya T, Kelsch RD, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003 95 5 586 593 10.1067/moe.2003.31 12738950 (Pubitemid 36886706)
47. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Penner CR, Folpe AL, Budnick SD, Mod Pathol 2002 15 7 687 691 10.1097/01.MP.0000018973.17736.F8 12118104 (Pubitemid 34787302)
48. KIT expression and activation in adenoid cystic carcinoma [abstract]. Oliveira AM, Hornick JL, Duensing A, Medeiros F, Fletcher CDM, Fletcher JA, Mod Pathol 2003 16 221A
49. Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study. Guigay JM, Bidault F, Temam S, Janot F, Raymond E, Faivre S, Proc Am Soc Clin Oncol 2007 25 bstr 6086
50. Imatinib with cisplatin in recurrent and/or metastatic adenoidcystic carcinoma-preliminary results of a phase II study of 18 patients with response assessed by morphological and functional imaging. Slevin NJ, Mais KL, Bruce I, Eur J Cancer Supplements 2005 3 292 293
51. Eff ects of imatinib mesylate on adenoid cystic carcinomas. Ochel HJ, Gademann G, Rocken C, Wordehoff H, Anticancer Res 2005 25 3659 3664 16101197 (Pubitemid 41105258)
52. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL, Head Neck 2005 27 1022 1027 10.1002/hed.20274 16265655 (Pubitemid 41705578)
53. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. Hotte SJ, Winquist EW, Lamont E, et al. J Clin Oncol 2005 23 585 590 15659505 (Pubitemid 46224236)
54. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M, Oral Oncol 2007 43 33 36 10.1016/j.oraloncology.2005. 12.026 16757202 (Pubitemid 46162246)
55. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Alcedo JC, Fabrega JM, Arosemena JR, et al. Head Neck 2004 26 829 831 10.1002/hed.20094 15350030 (Pubitemid 39159307)
56. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. Faivre S, Raymond E, Casiraghi O, et al. J Clin Oncol 2005 23 6273 6274 author reply 10.1200/JCO.2005.01.6592
57. Immmunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Vered M, Braunstein E, Buchner A, Head Neck 2002 24 632 636 10.1002/hed.10104 12112535 (Pubitemid 34734357)
58. Phase II trial of gefitinib in patients with incurable salivary gland cancer. Glisson B, Blumenschein G, Francisco H, et al. Proc Am Soc Clin Oncol 2005 23 bstr 5532
59. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. Agulnik M, Cohen EW, Cohen RB, et al. J Clin Oncol 2007 25 25 3978 3984 10.1200/JCO.2007.11.8612 17761983 (Pubitemid 47477277)
60. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Locati LD, Bossi P, Perrone F, et al. Oral Oncol 2009 45 574 578 10.1016/j.oraloncology.2008.07.010 18804410
61. C-erbB-2/neu oncogene and Ki67 analysis in the assessment of palatal salivary gland neoplasms. Giannoni C, El-Naggar AK, Ordnoez NG, Tu ZN, Austin J, Luna MA, Batsakis JG, Otolaryngol. Head Neck Surg. 1995 112 391 398 10.1016/S0194-5998(95)70272-5 7870438
62. Expression of C-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Ootsuki K, Terakado N, Matsumura T, Anticancer Res. 1995 15 2623 2626 8669836 (Pubitemid 26095072)
63. Adenoid cystic carcinoma: a retrospective clinical review. Khan AJ, Digiovanna MP, Ross DA, Sasaki CT, Carter D, Son YH, Haffty BG, Int. J. Cancer 2001 96 149 158 10.1002/ijc.1013 11410883 (Pubitemid 32520669)
64. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Glisson B, Colevas AD, Haddad R, et al. Clin Cancer Res 2004 10 3 944 946 10.1158/1078-0432.CCR-03-0253 14871971 (Pubitemid 38198894)
65. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. Dori S, Vered M, David R, et al. J Oral Pathol Med 2002 31 463 467 10.1034/j.1600-0714.2002.00017.x 12220353
66. Proliferating cell nuclear antigen and C-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Cho KJ, Lee SS, Lee YS, Head Neck 1999 21 414 419 10.1002/(SICI)1097-0347(199908)21:5<414::AID-HED6>3. 0.CO;2-M 10402521
67. C-erbB-2 oncogene expression in salivary gland tumours. Karja V, Syrjanen S, Kataja V, Syrjanen K, ORL J Otorhinolaryngol Relat Spec 1994 56 4 206 212 10.1159/000276657 7915830 (Pubitemid 24183197)
68. Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. Kerhonan NM, Blessing K, King G, Corbett IP, Miller ID, J Pathol 1991 163 1 77 80 10.1002/path.1711630113 1672154
69. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Sugano S, Mukai K, Tsuda H, Hirohashi S, Furuya S, Shimosato Y, et al. Laryngoscope 1992 102 8 923 927 10.1288/00005537-199208000-00013 1353853
70. Expressions of oncogene products in adenoid cystic carcinomas of salivary glands: immunohistochemical study. Kusafuka K, Kobubyo Gakkai Zasshi 1991 58 4 696 717
71. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Press MF, Pike MC, Hung G, et al. Cancer Res 1994 54 21 5675 5682 7522962 (Pubitemid 24346266)
72. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Weed DT, Gomez-Fernandez C, Pacheco J, et al. Head Neck 2004 26 4 353 364 10.1002/hed.10387 15054739 (Pubitemid 38436675)
73. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL, Grizzle WE, Laryngoscope 2001 111 8 1373 1378 10.1097/00005537- 200108000-00011 11568571 (Pubitemid 32730182)
74. Rare expression of the c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. Shrestha P, Huang JW, Tsuji T, Shinozaki F, Maeda K, Sasaki K, et al. J Oral Pathol Med 1992 21 477 480 10.1111/j.1600-0714.1992. tb00978.x 1361005
75. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Jaehne M, Roeser K, Jaekel T, et al. Cancer 2005 103 12 2526 2533 10.1002/cncr.21116 15900577 (Pubitemid 40800531)
76. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Nabili V, Tan JW, Bhuta S, et al. Head Neck 2007 29 10 907 912 10.1002/hed.20614 17563907
77. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Haddad R, Colevas AD, Krane JF, et al. Oral Oncol 2003 39 7 724 727 10.1016/S1368-8375(03)00097-6 12907212 (Pubitemid 36930120)
78. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Prat A, Parera M, Reyes V, et al. Head Neck 2008 30 5 680 683 10.1002/hed.20714 17972317 (Pubitemid 351656111)
79. Biological therapy of salivary duct carcinoma. Nashed M, Casasola RJ, J Laryngol Otol 2009 123 2 250 252 10.1017/S0022215108002314 18405406
80. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Kaidar-Person O, Billan S, Kuten A, Med Oncol 2011 Mar 6 [Epub ahead of print]
81. Expressions of nuclear factor kappa B, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Zhang J, Peng B, Chen X, Clin Cancer Res 2005 11 20 7334 7343 10.1158/1078-0432.CCR-05-0241 16243805 (Pubitemid 41507692)
82. NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. Zhang J, Peng B, Cell Prolif. 2009 42 150 161 10.1111/j.1365-2184.2009.00588.x 19317804
83. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Argiris A, Ghebremichael M, Burtness B, et al. Cancer 2011 117 3374 3382 10.1002/cncr.25852 21246525
84. Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Dori S, Trougouboff P, David R, Buchner A, Oral Oncol 2000 36 450 453 10.1016/S1368-8375(00)00029-4 10964052 (Pubitemid 30645980)
85. Estrogen receptor assay in polymorphous lowgrade adenocarcinoma and adenoid cystic carcinoma of salivary gland origin. Miller AS, Hartman GG, Chen SY, Edmonds PR, Brightman SA, Harwick RD, An immunohistochemical study. Oral Surg Oral Med Oral Pathol 1994 77 1 36 40
86. Estrogen receptors in parotid tumors. Gaffney EV, Pinkston JA, Eidson JJ, Endocr Res 1995 21 635 643 10.3109/07435809509030479 7588432
87. Estrogen receptor expression in salivary gland mucoepidermoid carcinoma and adenoid cystic carcinoma. Pires FR, Perez DE, Almeida OP, Kowalski LP, Pathol Oncol Res 2004 10 3 166 168 10.1007/BF03033746 15448753 (Pubitemid 39421996)
88. Estrogen receptors in normal salivary gland and salivary gland carcinoma. Dimery IW, Jones LA, Verjan RP, Raymond AK, Goepfert H, Hong WK, Arch Otolaryngol Head Neck Surg 1987 113 1082 1085 10.1001/archotol.1987. 01860100060022 3620130 (Pubitemid 18058225)
89. Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Shick PC, Riordan GP, Foss RD, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 80 4 440 444 10.1016/S1079-2104(05)80338-5 8521108
90. Immunohistochemical detection of oestrogen and progesterone receptors in human salivary gland tumours. Jeannon JP, Soames JV, Bell H, Wilson JA, Clin Otolaryngol 1999 24 1 52 54 10.1046/j.1365-2273.1999.00211.x 10196649 (Pubitemid 29116479)
91. Immunohistochemical localization of estradiol, progesterone, and progesterone receptor in human salivary glands and salivary adenoid cystic carcinomas. Ozono S, Onozuka M, Sato K, Ito Y, Cell Struct Funct 1992 17 169 175 10.1247/csf.17.169 1322800
92. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Fan CY, Melhem MF, Hosal AS, et al. Arch Otolaryngol Head Neck Surg 2001 127 9 1075 1079 11556855
93. The response of adenoid cystic carcinoma to tamoxifen. Shadaba A, Gaze MN, Grant HR, J Laryngol 1997 111 12 1186 1189 (Pubitemid 28040657)
94. Tamoxifen for salivary gland adenoid cystic carcinoma: a report of two cases. Elkin AD, Jacobs CD, J Cancer Res Clin Oncol 2008 134 1151 1153 10.1007/s00432-008-0377-3 18347813
95. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Locati LD, Quattrone P, Bossi P, et al. Ann Oncol 2003 14 8 1327 1328 10.1093/annonc/mdg331 12881399 (Pubitemid 37039062)
96. Partial remission of parotid gland carcinoma after goserelin. Van der Hulst RW, Van Krieken JH, Van der Kwast TH, et al. Lancet 1994 344 817 7916094 (Pubitemid 24283970)
97. 96- www.clinicaltrials.gov